Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
| Previous close | 1,509.90 |
| Open | 1,510.35 |
| Bid | 1,515.15 x 0 |
| Ask | 1,516.55 x 0 |
| Day's range | 1,503.90 - 1,518.30 |
| 52-week range | 977.50 - 1,638.70 |
| Volume | |
| Avg. volume | 114,368 |
| Market cap | 3.635T |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 38.00 |
| EPS (TTM) | 39.87 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | 12.50 (0.82%) |
| Ex-dividend date | 09 Feb 2024 |
| 1y target est | N/A |
Insider Monkey30 Most Valuable Drug Companies in 2024
In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]
Insider MonkeyTop 20 Most Valuable Indian Companies
In this article, we will look into the top 20 most valuable Indian companies. If you want to skip our detailed analysis, you can go directly to the Top 5 Most Valuable Indian Companies. An Outlook of the Indian Economy According to Deloitte’s Indian Economic Outlook 2023, The Indian economy is poised to emerge as […]
GlobeNewswireNidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern
